Clinical Trials on Extrahepatic Cholestasis in United Kingdom

Total 331 results

Children's Hospital Medical Center, Cincinnati
Wuhan Union Hospital, China

Not yet recruiting

Intestinal Microbiome Composition in Infants With Biliary Atresia (BA) (BA)

Biliary Atresia | Intrahepatic Cholestases | Normal Controls

United States
Guy's and St Thomas' NHS Foundation Trust
King's College London

Unknown

Bile Acid Effects in Fetal Arrhythmia Study (BEATS)

Intrahepatic Cholestasis of Pregnancy | Cholestasis of Pregnancy | Obstetric Cholestasis

United Kingdom
Albireo

Completed

An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects

Primary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver Diseases

United Kingdom
Mirum Pharmaceuticals, Inc.

Completed

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis (INDIGO)

Progressive Familial Intrahepatic Cholestasis (PFIC)

United States, United Kingdom, Poland, France
Mirum Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

United States, Argentina, France, Singapore, United Kingdom, Belgium, Turkey, Austria, Brazil, Canada, Colombia, Germany, Italy, Lebanon, Mexico, Poland
Mirum Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) (MARCH-PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Italy, United States, Argentina, France, Singapore, United Kingdom, Austria, Brazil, Mexico, Lebanon, Germany, Turkey, Poland, Belgium, Canada, Colombia, Hungary
Mirum Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). (RISE)

Cholestatic Liver Disease | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis

United States, United Kingdom, France, Belgium, Poland, Brazil, Mexico
Albireo

Active, not recruiting

Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Progressive Familial Intrahepatic Cholestasis

United States, Spain, Netherlands, United Kingdom, Turkey, Canada, Italy, Germany, France, Israel, Australia, Belgium, Poland, Saudi Arabia, Sweden
Albireo

Approved for marketing

Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis

Progressive Familial Intrahepatic Cholestasis

United States
Imperial College London

Completed

The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus

Gestational Diabetes Mellitus | Intrahepatic Cholestasis of Pregnancy

United Kingdom
King's College Hospital NHS Trust
European Association for the Study of the Liver

Recruiting

Liver Disease in Pregnancy

Cirrhosis, Liver | HELLP Syndrome | Intrahepatic Cholestasis of Pregnancy | Pregnancy Disease | AFLP - Acute Fatty Liver of Pregnancy

United Kingdom
Mirum Pharmaceuticals, Inc.

Terminated

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) (OHANA)

Intrahepatic Cholestasis of Pregnancy

United States, United Kingdom, New Zealand
University of Southern California

Completed

Randomized Trial of Wire and Sphincterotome Systems for Biliary Cannulation

Cholestasis, Extrahepatic

United States
Boston Scientific Corporation

Completed

A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction

Cholestasis, Extrahepatic

United States
Light Chain Bioscience - Novimmune SA

Terminated

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (PIANO)

Primary Biliary Cirrhosis

Italy, United Kingdom
University of Birmingham
University Hospital Birmingham NHS Foundation Trust; Intercept Pharmaceuticals

Terminated

EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study (EXCITED)

Primary Biliary Cholangitis

United Kingdom
Guy's and St Thomas' NHS Foundation Trust
King's College Hospital NHS Trust

Unknown

Paternally Inherited Phenotypes in Cholestasis (PIP-C)

Primary Sclerosing Cholangitis | Cholestasis | Primary Biliary Cirrhosis

United Kingdom
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle University; National Institute for Health Research, United Kingdom; Department of Health, United Kingdom

Completed

B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis (RITPBC)

Fatigue | Primary Biliary Cirrhosis

United Kingdom
Fast Forward Pharmaceuticals

Unknown

Pilot Study of FFP104 Dose Escalation in PBC Subjects

Primary Biliary Cirrhosis

Netherlands, United Kingdom
University of Alberta
GlaxoSmithKline; Axcan Pharma

Completed

Study of Combivir for Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Canada, United Kingdom
Mirum Pharmaceuticals, Inc.

Completed

Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease

Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis

United States, Canada
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Cholestatic Pruritus

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus

Cholestasis, Intrahepatic

United Kingdom
Mirum Pharmaceuticals, Inc.

Active, not recruiting

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study (MERGE)

Cholestatic Liver Disease

United States, France, United Kingdom, Canada, Belgium, Poland, Australia, Spain
Perspectum

Completed

Repeatability and Reproducibility of Quantitative MRCP

Liver Diseases | Primary Sclerosing Cholangitis | Gallstones | Primary Biliary Cirrhosis

United Kingdom
Intercept Pharmaceuticals

Terminated

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, Spain, Canada, United Kingdom, France, Germany, Austria, Netherlands
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
Mirum Pharmaceuticals, Inc.

Withdrawn

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (CASCADE)

Primary Biliary Cirrhosis

United States, United Kingdom
CymaBay Therapeutics, Inc.

Recruiting

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Hepatic Impairment | Compensated Cirrhosis | Primary Biliary Cholangitis

Korea, Republic of, United States, Spain, United Kingdom
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Novartis Pharmaceuticals

Completed

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Primary Biliary Cholangitis

United States, Germany, Russian Federation, Canada, United Kingdom, Poland
Mirum Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (CLARITY)

Primary Biliary Cirrhosis | PBC

United States, United Kingdom, Canada
Mirum Pharmaceuticals, Inc.

Completed

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) (IMAGINE)

Alagille Syndrome

United Kingdom
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (IMAGO)

Alagille Syndrome

United Kingdom
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
Genfit

Completed

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cholangitis (PBC)

United States, United Kingdom, France, Germany, Spain
University of California, Davis

Completed

Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients

Primary Biliary Cirrhosis

United States
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
CymaBay Therapeutics, Inc.

Completed

Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Germany, United Kingdom, Canada
The Cleveland Clinic

Completed

Pentoxifylline for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Group

Completed

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES PBC)

Primary Biliary Cholangitis

United States
National Institute of Diabetes and Digestive and...

Completed

Ursodiol-Methotrexate for Primary Biliary Cirrhosis

Liver Cirrhosis, Biliary

United States
University of Florida
Shionogi Inc.; The PBCers Organization

Completed

Use of Fenofibrate for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
University of Miami
Mayo Clinic

Withdrawn

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Mayo Clinic

Active, not recruiting

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
Mayo Clinic
UCB Pharma

Completed

Moexipril for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Christopher Bowlus, MD
Bristol-Myers Squibb

Completed

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
University of California, Davis
Genentech, Inc.

Completed

Initial Study of Rituximab to Treat Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Mayo Clinic
American College of Gastroenterology

Completed

Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC) (PBC)

Fatigue | Primary Biliary Cirrhosis

United States
Kowa Research Institute, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

Primary Biliary Cholangitis

United States, Japan

Clinical Trials on Extrahepatic Cholestasis in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations